PortfoliosLab logo
PortfoliosLab logo
Tools
Portfolios
Screeners
Discussions
NBIX vs. KNSL
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

NBIX vs. KNSL

Last updated May 24, 2025

Compare and contrast key facts about Neurocrine Biosciences, Inc. (NBIX) and Kinsale Capital Group, Inc. (KNSL).

Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: NBIX or KNSL.

Correlation

The correlation between NBIX and KNSL is 0.36, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Performance

NBIX vs. KNSL - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Neurocrine Biosciences, Inc. (NBIX) and Kinsale Capital Group, Inc. (KNSL). The values are adjusted to include any dividend payments, if applicable.

Loading data...

Key characteristics

Sharpe Ratio

NBIX:

-0.35

KNSL:

0.50

Sortino Ratio

NBIX:

-0.19

KNSL:

0.96

Omega Ratio

NBIX:

0.97

KNSL:

1.15

Calmar Ratio

NBIX:

-0.34

KNSL:

0.63

Martin Ratio

NBIX:

-0.74

KNSL:

2.11

Ulcer Index

NBIX:

19.50%

KNSL:

9.71%

Daily Std Dev

NBIX:

41.85%

KNSL:

39.84%

Max Drawdown

NBIX:

-97.21%

KNSL:

-38.24%

Current Drawdown

NBIX:

-21.60%

KNSL:

-15.28%

Fundamentals

Market Cap

NBIX:

$11.79B

KNSL:

$10.56B

EPS

NBIX:

$2.95

KNSL:

$17.36

PE Ratio

NBIX:

40.38

KNSL:

26.10

PEG Ratio

NBIX:

0.27

KNSL:

1.73

PS Ratio

NBIX:

4.89

KNSL:

6.45

PB Ratio

NBIX:

4.71

KNSL:

6.67

Total Revenue (TTM)

NBIX:

$2.41B

KNSL:

$1.64B

Gross Profit (TTM)

NBIX:

$2.37B

KNSL:

$1.64B

EBITDA (TTM)

NBIX:

$539.80M

KNSL:

$637.14M

Returns By Period

In the year-to-date period, NBIX achieves a -11.96% return, which is significantly lower than KNSL's -0.29% return.

NBIX

YTD

-11.96%

1M

16.43%

6M

-4.35%

1Y

-14.47%

3Y*

12.41%

5Y*

-0.75%

10Y*

11.01%

KNSL

YTD

-0.29%

1M

-5.71%

6M

-6.97%

1Y

19.89%

3Y*

31.21%

5Y*

25.54%

10Y*

N/A

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

Neurocrine Biosciences, Inc.

Kinsale Capital Group, Inc.

Risk-Adjusted Performance

NBIX vs. KNSL — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.
NBIX
The Risk-Adjusted Performance Rank of NBIX is 3232
Overall Rank
The Sharpe Ratio Rank of NBIX is 3333
Sharpe Ratio Rank
The Sortino Ratio Rank of NBIX is 3232
Sortino Ratio Rank
The Omega Ratio Rank of NBIX is 3030
Omega Ratio Rank
The Calmar Ratio Rank of NBIX is 3030
Calmar Ratio Rank
The Martin Ratio Rank of NBIX is 3636
Martin Ratio Rank
KNSL
The Risk-Adjusted Performance Rank of KNSL is 7171
Overall Rank
The Sharpe Ratio Rank of KNSL is 7171
Sharpe Ratio Rank
The Sortino Ratio Rank of KNSL is 6565
Sortino Ratio Rank
The Omega Ratio Rank of KNSL is 6868
Omega Ratio Rank
The Calmar Ratio Rank of KNSL is 7777
Calmar Ratio Rank
The Martin Ratio Rank of KNSL is 7474
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

NBIX vs. KNSL - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Neurocrine Biosciences, Inc. (NBIX) and Kinsale Capital Group, Inc. (KNSL). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current NBIX Sharpe Ratio is -0.35, which is lower than the KNSL Sharpe Ratio of 0.50. The chart below compares the historical Sharpe Ratios of NBIX and KNSL, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Loading data...

Dividends

NBIX vs. KNSL - Dividend Comparison

NBIX has not paid dividends to shareholders, while KNSL's dividend yield for the trailing twelve months is around 0.13%.

TTM202420232022202120202019201820172016
NBIX
Neurocrine Biosciences, Inc.		0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
KNSL
Kinsale Capital Group, Inc.		0.13%0.13%0.17%0.20%0.18%0.18%0.31%0.50%0.53%0.29%

Drawdowns

NBIX vs. KNSL - Drawdown Comparison

The maximum NBIX drawdown since its inception was -97.21%, which is greater than KNSL's maximum drawdown of -38.24%. Use the drawdown chart below to compare losses from any high point for NBIX and KNSL. For additional features, visit the drawdowns tool.

Loading data...

Volatility

NBIX vs. KNSL - Volatility Comparison

The current volatility for Neurocrine Biosciences, Inc. (NBIX) is 11.43%, while Kinsale Capital Group, Inc. (KNSL) has a volatility of 20.70%. This indicates that NBIX experiences smaller price fluctuations and is considered to be less risky than KNSL based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Loading data...

Financials

NBIX vs. KNSL - Financials Comparison

This section allows you to compare key financial metrics between Neurocrine Biosciences, Inc. and Kinsale Capital Group, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.

Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities

100.00M200.00M300.00M400.00M500.00M600.00M20212022202320242025
572.60M
423.40M
(NBIX) Total Revenue
(KNSL) Total Revenue
Values in USD except per share items

NBIX vs. KNSL - Profitability Comparison

The chart below illustrates the profitability comparison between Neurocrine Biosciences, Inc. and Kinsale Capital Group, Inc. over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.
Gross Margin
Operating Margin
Net Margin
Quarterly
Annual
97.5%98.0%98.5%99.0%99.5%100.0%20212022202320242025
98.4%
100.0%
(NBIX) Gross Margin
(KNSL) Gross Margin
NBIX - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, Neurocrine Biosciences, Inc. reported a gross profit of 563.40M and revenue of 572.60M. Therefore, the gross margin over that period was 98.4%.

KNSL - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, Kinsale Capital Group, Inc. reported a gross profit of 423.40M and revenue of 423.40M. Therefore, the gross margin over that period was 100.0%.

NBIX - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, Neurocrine Biosciences, Inc. reported an operating income of 23.60M and revenue of 572.60M, resulting in an operating margin of 4.1%.

KNSL - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, Kinsale Capital Group, Inc. reported an operating income of 114.87M and revenue of 423.40M, resulting in an operating margin of 27.1%.

NBIX - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, Neurocrine Biosciences, Inc. reported a net income of 7.90M and revenue of 572.60M, resulting in a net margin of 1.4%.

KNSL - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, Kinsale Capital Group, Inc. reported a net income of 89.23M and revenue of 423.40M, resulting in a net margin of 21.1%.